Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT324 + BNT327
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**BNT324 + BNT327** is a combination investigational therapy currently in clinical development for advanced, metastatic, or relapsed/progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)[1][5][7][8][9].\n- **BNT324** is a B7-H3 antibody-drug conjugate (ADC), designed to deliver a cytotoxic payload specifically to cells expressing the B7-H3 antigen, commonly found on various tumor cells.\n- **BNT327** is a bispecific monoclonal antibody simultaneously targeting programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF), aiming to inhibit immune evasion (via PD-L1 blockade) and tumor angiogenesis (via VEGF inhibition)[1][2][3][5].\nThe combination is being evaluated for synergistic antitumor effects and is intended as an alternative to chemotherapy regimens for patients with advanced SCLC and NSCLC[3][5][6].\nBioNTech leads development, with DualityBio as the ADC originator for BNT324[3][5][6].
- Brand names
- BNT324 + BNT327
- Other names
- BNT324BNT-324BNT 324BNT327BNT-327BNT 327BNT324 + BNT327
02
Targets
Beyond the preview
Go deeper on BNT324 + BNT327.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT324 + BNT327.